We would like to thank Professor Parsons for his interest and comments concerning our manuscript "Cytotoxicity of Oxycodone and Morphine in Human Neuroblastoma and Mouse Motoneuronal Cells: A Comparative Approach" \[[@CR1]\]. We totally agree with Parsons that the choice of appropriate cell model is of paramount importance in in vitro drug toxicity testing \[[@CR2]\]. Moreover, using at least two cell lines and two toxicity assays is endorsed in order to have more accurate and relevant interpretation of drug toxicity for clinical use. In our study, we have used the SH-SY5Y and NSC-34 cell lines, and 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and resazurin reduction assays, all of which are commonly used for assessing the toxicity of different compounds. In the present study, the toxicity of both compounds, oxycodone and morphine, appeared to be similar in both cell lines and both assays.

The main focus of the letter to the editor by Parsons is that the two cell lines used in our study were not differentiated prior to neurotoxicity testing. Use of transformed cell lines is a widely used approach in scientific literature to get 'quick answers for easy questions'. We are not claiming that the cell models used were the most optimal. However, these two cell lines, the SH-SY5Y and NSC-34 cell lines, are widely used and were available on our campus. Moreover, we have expertise for resazurin and classical MTT tests, both commonly accepted as accurate methods in this kind of evaluation. In this study, the first endpoint tested was cell viability. Both cell lines resulted in a comparable outcome for 'toxic' concentrations, which were well above those reached in clinical work. Therefore, further studies were carried out with SH-SY5Y cells only, which are routinely used in in vitro neurotoxic studies. Based on the PubMed search, \>620 studies targeting neurotoxicity as an endpoint have been carried out with SH-SY5Y cells thus far. Our proof-of-concept data should be considered as preliminary 'kick-offs' for further studies with additional cell signaling, 'omics', or any other more specific endpoints. For more conclusive studies, more relevant differentiated cell lines of human origin should be used as proposed by Parsons.

We agree with Parsons that the results based on in vitro cell models may not replicate in vivo phenotypes \[[@CR2]\], and thus, as we wrote, ideally a complete roster of histologic, physiologic, and behavioral testing should be performed on spinal drugs in two or more animal species, followed by safety trials in humans prior to widespread clinical use \[[@CR1]\].

In conclusion, the results of our study \[[@CR1]\] should be considered as preliminary data on the neurotoxicity of epidural oxycodone. The data support our clinical experience with several decades of epidural infusion of oxycodone in palliative care and our study hypothesis that neurotoxicity of oxycodone may not be inferior to that of morphine. However, further studies and close follow-up of patients are required for epidural pain management in the most vulnerable patient groups.
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